Emergent BioSolutions Inc. (EBS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,577 | 1,774 | 1,118 | 1,049 | 1,044 | 743 | 770 | 657 |
| Operating profit | $m | 110 | -54 | ||||||
| Net profit | $m | 306 | 220 | -212 | -760 | -191 | 53 | -177 | 19 |
| EPS reported | $ | 0.93 | -3.55 | ||||||
| Operating cashflow per share | $ | 3.19 | 1.89 | ||||||
| Capex per share | $ | 0.26 | 0.23 | ||||||
| FCF per share | $ | 2.93 | 1.66 | ||||||
| Free cash flow | $m | 157 | 86 | ||||||
| Net debt | $m | 367 | 442 | ||||||
| Book value equity | $m | 523 | 341 | ||||||
| Book value per share | $ | 9.22 | 6.62 | ||||||
| Number of shares | m | 56.7 | 51.6 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 13.29 | - | ||||||
| P/B LTM | x | 1.27 | 1.94 | ||||||
| P/S LTM | x | 0.89 | 0.86 | ||||||
| P/FCF LTM | x | 4.22 | 7.70 | ||||||
| EV/EBITDA LTM | x | 4.28 | -43.37 | ||||||
| EV/Sales LTM | x | 1.38 | 0.88 | ||||||
| Earnings Yield LTM | % | +7.52% | -74.65% | ||||||
| FCF Yield | % | +23.71% | +12.99% | ||||||
| Quality | |||||||||
| ROE | % | +10.07% | -35.91% | ||||||
| ROIC | % | +5.90% | -5.47% | ||||||
| Operating margin | % | +14.83% | -7.06% | ||||||
| Gross margin | % | +47.19% | +49.40% | ||||||
| FCF/Sales | % | +21.11% | +11.15% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -28.81% | -26.20% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | +337.99% | +139.94% | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.27 | 0.15 | ||||||
| Net Debt/EBITDA | x | 1.53 | -18.65 | ||||||
| EBIT/Net interest | x | 1.86 | -1.07 | ||||||
| Net debt/market cap | % | +86.52% | +2.46% | ||||||
| Net debt/Equity | x | 0.70 | 1.29 | ||||||
| Gross debt/equity | x | 1.09 | 1.70 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free